Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study
Summary Background Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congeni...
Gespeichert in:
| Veröffentlicht in: | Pediatric pulmonology 2015-10, Vol.50 (10), p.1025-1032 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1032 |
|---|---|
| container_issue | 10 |
| container_start_page | 1025 |
| container_title | Pediatric pulmonology |
| container_volume | 50 |
| creator | Ozyurt, Abdullah Narin, Nazmi Baykan, Ali Argun, Mustafa Pamukcu, Ozge Zararsiz, Gokmen Sunkak, Suleyman Uzum, Kazim |
| description | Summary
Background
Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.
Methods
A total of 91 infants with CHD who received palivizumab prophylaxis and 96 infants with CHD without prophylaxis (0–12 months:52; 12–24 months:44) were included in this single‐center retrospective case control study. Data on patient characteristics, household environment, and LRTIs were evaluated.
Results
In patients without prophylaxis, the rate of overall lower respiratory tract infections (LRTIs) (P |
| doi_str_mv | 10.1002/ppul.23102 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1713527229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1713527229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4002-726d0bb61c793ac3a04c8bdad805d62adb2142a3c7ab83bdf89e862e331154353</originalsourceid><addsrcrecordid>eNp9kEtP3TAQhS3UqtxCN_0BlZcVUqgfsR13hxCllS4tC15iY01sh2vqPIiTQvrryeUCS1ZHmvnO0cxB6DMl-5QQ9q3rxrjPOCVsCy0o0TojuZbv0KJQQmSykHwbfUzplpB5p-kHtM0EFVIrvkD-qKqCBTvhtsIdxPAv_B9rKHHXt91qivAQEoa6bW5waCpohoTvw7DCdp74JgwQ8cpDP2AXkofkv-MDbGddA0PfRpyG0U276H0FMflPz7qDzn8cnR3-zJZ_jn8dHiwzm8-PZIpJR8pSUqs0B8uB5LYoHbiCCCcZuJLRnAG3CsqCl64qtC8k85xTKnIu-A76usmdr78bfRpMHZL1MULj2zEZqigXTDGmZ3Rvg9q-Tan3len6UEM_GUrMulazrtU81TrDX55zx7L27hV96XEG6Aa4D9FPb0SZ09Pz5UtotvGENPiHVw_0f41UXAlz-fvYnOiTs6uL5bW54o8TXJN7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1713527229</pqid></control><display><type>article</type><title>Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Ozyurt, Abdullah ; Narin, Nazmi ; Baykan, Ali ; Argun, Mustafa ; Pamukcu, Ozge ; Zararsiz, Gokmen ; Sunkak, Suleyman ; Uzum, Kazim</creator><creatorcontrib>Ozyurt, Abdullah ; Narin, Nazmi ; Baykan, Ali ; Argun, Mustafa ; Pamukcu, Ozge ; Zararsiz, Gokmen ; Sunkak, Suleyman ; Uzum, Kazim</creatorcontrib><description><![CDATA[Summary
Background
Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.
Methods
A total of 91 infants with CHD who received palivizumab prophylaxis and 96 infants with CHD without prophylaxis (0–12 months:52; 12–24 months:44) were included in this single‐center retrospective case control study. Data on patient characteristics, household environment, and LRTIs were evaluated.
Results
In patients without prophylaxis, the rate of overall lower respiratory tract infections (LRTIs) (P < 0.001), complicated LRTIs (P = 0.006), LRTI‐related hospitalization (P < 0.001) and ICU admission (P = 0.008) were significantly higher than control patients. Weight <10th percentile (odds ratio (OR) 5.78, 95% confidence interval (CI):1.37; 24.4, P < 0.001) and concomitant chromosome abnormality (OR 4.01, 95% CI:1.01;16.45, P < 0.001) in patients with prophylaxis, while presence of a sibling <11 years of age (OR 3.38, 95% CI: 1.21; 9.46, P < 0.001) and congestive heart failure (OR 8.63, 95% CI: 2.81; 26.6, P < 0.001) in the control group were the significant correlates of LRTI‐related hospitalization.
Conclusion
Our findings revealed significantly lower rate of overall and complicated LRTIs, LRTI‐related hospitalization and ICU admissions in infants with CHD via palivizumab prophylaxis. Pediatr Pulmonol. 2015; 50:1025–1032. © 2014 Wiley Periodicals, Inc.]]></description><identifier>ISSN: 8755-6863</identifier><identifier>EISSN: 1099-0496</identifier><identifier>DOI: 10.1002/ppul.23102</identifier><identifier>PMID: 25156973</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Antiviral Agents - therapeutic use ; Case-Control Studies ; clinical trials ; congenital heart disease ; Female ; Heart Defects, Congenital - epidemiology ; hospitalization ; Hospitalization - statistics & numerical data ; Humans ; Infant ; Infant, Newborn ; Intensive Care Units ; lower respiratory tract infections ; Male ; Palivizumab - therapeutic use ; palivizumab prophylaxis ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Tract Infections - epidemiology ; Respiratory Tract Infections - prevention & control ; Retrospective Studies ; risk factors ; RSV ; Turkey - epidemiology</subject><ispartof>Pediatric pulmonology, 2015-10, Vol.50 (10), p.1025-1032</ispartof><rights>2014 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4002-726d0bb61c793ac3a04c8bdad805d62adb2142a3c7ab83bdf89e862e331154353</citedby><cites>FETCH-LOGICAL-c4002-726d0bb61c793ac3a04c8bdad805d62adb2142a3c7ab83bdf89e862e331154353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fppul.23102$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fppul.23102$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25156973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ozyurt, Abdullah</creatorcontrib><creatorcontrib>Narin, Nazmi</creatorcontrib><creatorcontrib>Baykan, Ali</creatorcontrib><creatorcontrib>Argun, Mustafa</creatorcontrib><creatorcontrib>Pamukcu, Ozge</creatorcontrib><creatorcontrib>Zararsiz, Gokmen</creatorcontrib><creatorcontrib>Sunkak, Suleyman</creatorcontrib><creatorcontrib>Uzum, Kazim</creatorcontrib><title>Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study</title><title>Pediatric pulmonology</title><addtitle>Pediatr Pulmonol</addtitle><description><![CDATA[Summary
Background
Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.
Methods
A total of 91 infants with CHD who received palivizumab prophylaxis and 96 infants with CHD without prophylaxis (0–12 months:52; 12–24 months:44) were included in this single‐center retrospective case control study. Data on patient characteristics, household environment, and LRTIs were evaluated.
Results
In patients without prophylaxis, the rate of overall lower respiratory tract infections (LRTIs) (P < 0.001), complicated LRTIs (P = 0.006), LRTI‐related hospitalization (P < 0.001) and ICU admission (P = 0.008) were significantly higher than control patients. Weight <10th percentile (odds ratio (OR) 5.78, 95% confidence interval (CI):1.37; 24.4, P < 0.001) and concomitant chromosome abnormality (OR 4.01, 95% CI:1.01;16.45, P < 0.001) in patients with prophylaxis, while presence of a sibling <11 years of age (OR 3.38, 95% CI: 1.21; 9.46, P < 0.001) and congestive heart failure (OR 8.63, 95% CI: 2.81; 26.6, P < 0.001) in the control group were the significant correlates of LRTI‐related hospitalization.
Conclusion
Our findings revealed significantly lower rate of overall and complicated LRTIs, LRTI‐related hospitalization and ICU admissions in infants with CHD via palivizumab prophylaxis. Pediatr Pulmonol. 2015; 50:1025–1032. © 2014 Wiley Periodicals, Inc.]]></description><subject>Antiviral Agents - therapeutic use</subject><subject>Case-Control Studies</subject><subject>clinical trials</subject><subject>congenital heart disease</subject><subject>Female</subject><subject>Heart Defects, Congenital - epidemiology</subject><subject>hospitalization</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Intensive Care Units</subject><subject>lower respiratory tract infections</subject><subject>Male</subject><subject>Palivizumab - therapeutic use</subject><subject>palivizumab prophylaxis</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory Tract Infections - epidemiology</subject><subject>Respiratory Tract Infections - prevention & control</subject><subject>Retrospective Studies</subject><subject>risk factors</subject><subject>RSV</subject><subject>Turkey - epidemiology</subject><issn>8755-6863</issn><issn>1099-0496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtP3TAQhS3UqtxCN_0BlZcVUqgfsR13hxCllS4tC15iY01sh2vqPIiTQvrryeUCS1ZHmvnO0cxB6DMl-5QQ9q3rxrjPOCVsCy0o0TojuZbv0KJQQmSykHwbfUzplpB5p-kHtM0EFVIrvkD-qKqCBTvhtsIdxPAv_B9rKHHXt91qivAQEoa6bW5waCpohoTvw7DCdp74JgwQ8cpDP2AXkofkv-MDbGddA0PfRpyG0U276H0FMflPz7qDzn8cnR3-zJZ_jn8dHiwzm8-PZIpJR8pSUqs0B8uB5LYoHbiCCCcZuJLRnAG3CsqCl64qtC8k85xTKnIu-A76usmdr78bfRpMHZL1MULj2zEZqigXTDGmZ3Rvg9q-Tan3len6UEM_GUrMulazrtU81TrDX55zx7L27hV96XEG6Aa4D9FPb0SZ09Pz5UtotvGENPiHVw_0f41UXAlz-fvYnOiTs6uL5bW54o8TXJN7</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Ozyurt, Abdullah</creator><creator>Narin, Nazmi</creator><creator>Baykan, Ali</creator><creator>Argun, Mustafa</creator><creator>Pamukcu, Ozge</creator><creator>Zararsiz, Gokmen</creator><creator>Sunkak, Suleyman</creator><creator>Uzum, Kazim</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study</title><author>Ozyurt, Abdullah ; Narin, Nazmi ; Baykan, Ali ; Argun, Mustafa ; Pamukcu, Ozge ; Zararsiz, Gokmen ; Sunkak, Suleyman ; Uzum, Kazim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4002-726d0bb61c793ac3a04c8bdad805d62adb2142a3c7ab83bdf89e862e331154353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Case-Control Studies</topic><topic>clinical trials</topic><topic>congenital heart disease</topic><topic>Female</topic><topic>Heart Defects, Congenital - epidemiology</topic><topic>hospitalization</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Intensive Care Units</topic><topic>lower respiratory tract infections</topic><topic>Male</topic><topic>Palivizumab - therapeutic use</topic><topic>palivizumab prophylaxis</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory Tract Infections - epidemiology</topic><topic>Respiratory Tract Infections - prevention & control</topic><topic>Retrospective Studies</topic><topic>risk factors</topic><topic>RSV</topic><topic>Turkey - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ozyurt, Abdullah</creatorcontrib><creatorcontrib>Narin, Nazmi</creatorcontrib><creatorcontrib>Baykan, Ali</creatorcontrib><creatorcontrib>Argun, Mustafa</creatorcontrib><creatorcontrib>Pamukcu, Ozge</creatorcontrib><creatorcontrib>Zararsiz, Gokmen</creatorcontrib><creatorcontrib>Sunkak, Suleyman</creatorcontrib><creatorcontrib>Uzum, Kazim</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric pulmonology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ozyurt, Abdullah</au><au>Narin, Nazmi</au><au>Baykan, Ali</au><au>Argun, Mustafa</au><au>Pamukcu, Ozge</au><au>Zararsiz, Gokmen</au><au>Sunkak, Suleyman</au><au>Uzum, Kazim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study</atitle><jtitle>Pediatric pulmonology</jtitle><addtitle>Pediatr Pulmonol</addtitle><date>2015-10</date><risdate>2015</risdate><volume>50</volume><issue>10</issue><spage>1025</spage><epage>1032</epage><pages>1025-1032</pages><issn>8755-6863</issn><eissn>1099-0496</eissn><abstract><![CDATA[Summary
Background
Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.
Methods
A total of 91 infants with CHD who received palivizumab prophylaxis and 96 infants with CHD without prophylaxis (0–12 months:52; 12–24 months:44) were included in this single‐center retrospective case control study. Data on patient characteristics, household environment, and LRTIs were evaluated.
Results
In patients without prophylaxis, the rate of overall lower respiratory tract infections (LRTIs) (P < 0.001), complicated LRTIs (P = 0.006), LRTI‐related hospitalization (P < 0.001) and ICU admission (P = 0.008) were significantly higher than control patients. Weight <10th percentile (odds ratio (OR) 5.78, 95% confidence interval (CI):1.37; 24.4, P < 0.001) and concomitant chromosome abnormality (OR 4.01, 95% CI:1.01;16.45, P < 0.001) in patients with prophylaxis, while presence of a sibling <11 years of age (OR 3.38, 95% CI: 1.21; 9.46, P < 0.001) and congestive heart failure (OR 8.63, 95% CI: 2.81; 26.6, P < 0.001) in the control group were the significant correlates of LRTI‐related hospitalization.
Conclusion
Our findings revealed significantly lower rate of overall and complicated LRTIs, LRTI‐related hospitalization and ICU admissions in infants with CHD via palivizumab prophylaxis. Pediatr Pulmonol. 2015; 50:1025–1032. © 2014 Wiley Periodicals, Inc.]]></abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25156973</pmid><doi>10.1002/ppul.23102</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8755-6863 |
| ispartof | Pediatric pulmonology, 2015-10, Vol.50 (10), p.1025-1032 |
| issn | 8755-6863 1099-0496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1713527229 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Antiviral Agents - therapeutic use Case-Control Studies clinical trials congenital heart disease Female Heart Defects, Congenital - epidemiology hospitalization Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Intensive Care Units lower respiratory tract infections Male Palivizumab - therapeutic use palivizumab prophylaxis Respiratory Syncytial Virus Infections - prevention & control Respiratory Tract Infections - epidemiology Respiratory Tract Infections - prevention & control Retrospective Studies risk factors RSV Turkey - epidemiology |
| title | Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A47%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20palivizumab%20prophylaxis%20among%20infants%20with%20congenital%20heart%20disease:%20A%20case%20control%20study&rft.jtitle=Pediatric%20pulmonology&rft.au=Ozyurt,%20Abdullah&rft.date=2015-10&rft.volume=50&rft.issue=10&rft.spage=1025&rft.epage=1032&rft.pages=1025-1032&rft.issn=8755-6863&rft.eissn=1099-0496&rft_id=info:doi/10.1002/ppul.23102&rft_dat=%3Cproquest_cross%3E1713527229%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1713527229&rft_id=info:pmid/25156973&rfr_iscdi=true |